Why the study?
Lp(a) testing is relatively infrequent in health systems across the U.S., and improved patient and provider education is needed to raise awareness as new therapies emerge.
Lipoprotein(a) testing remains infrequent in U.S. health systems, highlighting a need for improved provider and patient education as new targeted therapies emerge.
Answers are grounded in this paper and cite their sources.
Suggests gaps in Lp(a) awareness; leaves open optimal strategies to increase testing as therapies advance.
Lp(a) testing is relatively infrequent in health systems across the U.S. As new therapies for Lp(a) emerge, improved patient and provider education is needed to increase awareness of the utility of this risk marker.
No takes yet. Share an insight, caveat, or question.
Kelsey et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: